Duearity

Peter Arndt, one of Duearity's founders, was undergoing tinnitus retraining therapy (TRT) and noticed the treatment to be effective, but incompatible with daily life. Tinnitus retraining therapy is based on cognitive behavioral therapy and requires white noise to be played uninterrupted for 6-8 hours per day for 6-24 months. Wearing headphones for prolonged and uninterrupted period of time was interfering with work during daytime and with sleep during nighttime.

The founders set out to find a solution that did not require headphones and did not occupy the ear canals.Digital Health Technology News: [https://www.healthtechdigital.com/swedish-medtech-startup-starts-pre-sale-of-unique-product-for-tinnitus-treatment/ Swedish MedTech startup starts pre-sale of unique product for tinnitus treatment - Digital Health Technology News] {{Webarchive|url=https://web.archive.org/web/20220209003057/https://www.healthtechdigital.com/swedish-medtech-startup-starts-pre-sale-of-unique-product-for-tinnitus-treatment/ |date=9 February 2022 }}, accessdate: 6 december 2022MedTech Magazine: [https://www.medtechmagazine.se/article/view/833051/malmobolag_lanserar_produkt_for_egenbehandling_av_tinnitus?rel=related Malmöbolag lanserar produkt för egenbehandling av tinnitus - MedTech Magazine] {{Webarchive|url=https://web.archive.org/web/20221215173020/https://www.medtechmagazine.se/article/view/833051/malmobolag_lanserar_produkt_for_egenbehandling_av_tinnitus?rel=related |date=15 December 2022 }}, accessdate: 6 december 2022 In 2020, a proof of concept was successfully completed and the company applied for a patent.{{cite web | title=Duearity AB:s halvårsrapport för perioden 1 januari till 30 juni 2021 | website=Nasdaq News| date=2021-08-25 | url=https://view.news.eu.nasdaq.com/view?id=b3b414d08e5307c8a205ae0af800d7661&lang=sv | language=sv | access-date=2022-12-15}}{{cite web | title=Duearity 2022 Q3 | website=MFN |url=https://storage.mfn.se/0352446f-2290-4fd0-bdce-7542b5443896/q3-2022-duearity-ab.pdf | language=sv | access-date=2022-12-15}}

On 11 May 2021, the company's shares debuted on Nasdaq First North under ticker symbol DEAR. The company was previously called Cochlearity, but the name was changed pre-IPO in order to avoid mixup with another medtech company.MedTech Magazine: [https://www.medtechmagazine.se/article/view/778988/cochlearity_blir_duearity_infor_borsnotering Cochlearity blir Duearity inför börsnotering - MedTech Magazine] {{Webarchive|url=https://web.archive.org/web/20221215173203/https://www.medtechmagazine.se/article/view/778988/cochlearity_blir_duearity_infor_borsnotering |date=15 December 2022 }}, accessdate: 6 december 2022

75,3% of the IPO shares were subscribed before the IPO offer was made public.{{cite web | title=IPO Guide: Duearity| publisher= Affärsvärlden| url=https://www.affarsvarlden.se/ipo-guiden/bolag/duearity | access-date=2022-12-15}}{{cite web | last=Liedholm | first=Kim | title=Duearity vill hjälpa personer med tinnitusbesvär | website=BioStock | date=2021-04-20 | url=https://www.biostock.se/2021/04/duearity-vill-hjalpa-personer-med-tinnitusbesvar/ | language=sv | access-date=2022-12-15}} Duearity’s IPO was oversubscribed by 9 times.{{cite web | title=Duearitys emission kraftigt övertecknad | website=Dagens PS | date=2021-04-30 | url=https://www.dagensps.se/bors-finans/borsnoteringar/duearitys-emission-kraftigt-overtecknad/ | language=sv | access-date=2022-12-15}}

Duearity is focusing its products on white noise and tinnitus retraining therapy, which has been shown to be effective in a variety of research studies.{{cite journal |vauthors=Grewal R, Spielmann PM, Jones SE, Hussain SS |title=Clinical efficacy of tinnitus retraining therapy and cognitive behavioural therapy in the treatment of subjective tinnitus: a systematic review |journal=J Laryngol Otol |volume=128 |issue=12 |pages=1028–33 |date=December 2014 |pmid=25417546 |doi=10.1017/S0022215114002849 |s2cid=42092743 |url=}}{{cite journal |vauthors=Bauer CA, Berry JL, Brozoski TJ |title=The effect of tinnitus retraining therapy on chronic tinnitus: A controlled trial |journal=Laryngoscope Investig Otolaryngol |volume=2 |issue=4 |pages=166–177 |date=August 2017 |pmid=28894836 |pmc=5562945 |doi=10.1002/lio2.76 |url=}}{{cite journal |vauthors=Herraiz C, Hernandez FJ, Toledano A, Aparicio JM |title=Tinnitus retraining therapy: prognosis factors |journal=Am J Otolaryngol |volume=28 |issue=4 |pages=225–9 |date=2007 |pmid=17606035 |doi=10.1016/j.amjoto.2006.09.004 |url=}}{{cite journal |vauthors=Han M, Yang X, Lv J |title=Efficacy of tinnitus retraining therapy in the treatment of tinnitus: A meta-analysis and systematic review |journal=Am J Otolaryngol |volume=42 |issue=6 |pages=103151 |date=2021 |pmid=34303210 |doi=10.1016/j.amjoto.2021.103151 |url=}}

Since 2020, Duearity has been developing the world's smallest and most flexible tinnitus aid that emits white noise through bone conduction technology.BioStock: [https://www.biostock.se/2021/04/duearity-vill-hjalpa-personer-med-tinnitusbesvar/ Duearity vill hjälpa personer med tinnitusbesvär - BioStock] {{Webarchive|url=https://web.archive.org/web/20221215173048/https://www.biostock.se/2021/04/duearity-vill-hjalpa-personer-med-tinnitusbesvar/ |date=15 December 2022 }}, accessdate: 6 december 2022Duearity ska noteras på Nasdaq First North den 11 maj: [https://www.affarsvarlden.se/artikel/duearity-ska-noteras-pa-nasdaq-first-north Duearity ska noteras på Nasdaq First North den 11 maj] {{Webarchive|url=https://web.archive.org/web/20210509014236/https://www.affarsvarlden.se/artikel/duearity-ska-noteras-pa-nasdaq-first-north |date=9 May 2021 }}, accessdate: 6 december 2022 It is a patented medtech CE class IIa productSvensk Patentdatabas, Träfflista: [https://tc.prv.se/spd/search?content=Duearity&lang=sv&tab=1&hits=true Svensk Patentdatabas, Träfflista] {{Webarchive|url=https://web.archive.org/web/20221215173035/https://tc.prv.se/spd/search?content=Duearity&lang=sv&tab=1&hits=true |date=15 December 2022 }}, accessdate: 6 december 2022PRV avser att godkänna Duearitys patentansökan: [https://view.news.eu.nasdaq.com/view?id=b589eb0b982545d0e6e350ebda03b06d9&lang=sv PRV avser att godkänna Duearitys patentansökan] {{Webarchive|url=https://web.archive.org/web/20221215173036/https://view.news.eu.nasdaq.com/view?id=b589eb0b982545d0e6e350ebda03b06d9&lang=sv |date=15 December 2022 }}, accessdate: 6 december 2022 with FDA 510(k) clearance in the U.S.{{cite web | title=510(k) Notification | website=Food and Drug Administration – accessdata.fda.gov | date=2002-11-01 | url=https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K223694 | archive-url=https://web.archive.org/web/20240524060451/https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K223694 | archive-date=2024-05-24 | url-status=live | access-date=2024-05-24}}{{cite web | title=510(k) Summary | website=accessdata.fda.gov | date=2024-05-24 | url=https://www.accessdata.fda.gov/cdrh_docs/pdf22/K223694.pdf | archive-url=https://web.archive.org/web/20240524060742/https://www.accessdata.fda.gov/cdrh_docs/pdf22/K223694.pdf | archive-date=2024-05-24 | url-status=dead | access-date=2024-05-24}} It is a non-invasive device that attaches behind the ears and keeps the ear canals free.

Duearity is also developing a software for analysing tinnitus and managing its symptoms.{{cite web | title=Swedish Patent Database, Results list | website=Swedish Patent Database| date=2020-07-27 | url=https://tc.prv.se/spd/search?content=&number=544905&numberflag=&klass=&from=&to=&dateflag=&prionr=&applicant=&inventor=&representative=&cityzip=&cityzipflag=&tidnrtyp=&tidar_from=&tidnr_from=&tidar_tom=&tidnr_tom=&inforce=&system=&lang=en&hits=true&tab=2 | access-date=2022-12-14}} The company observes strong interest from researchers, audiologists and otorhinolaryngologists.

{{Reflist|30em}}

{{Finance links

| name = Duearity AB

| symbol = DEAR

| bloomberg = DEAR:SS

| yahoo = DEAR.ST

| google = DEAR:STO

}}

• [https://pubmed.ncbi.nlm.nih.gov/?term=Tinnitus+retraining+therapy Clinical research on Tinnitus retraining therapy]
• [https://storage.mfn.se/f407a39d-6431-449f-8725-e95369f3de11/arsredovisning-2021-duearity-ab-signerad.pdf Latest annual report (2021)]
• [https://nyemission.dk/wp-content/uploads/duearity.pdf IPO prospectus (2021)]
• [https://tc.prv.se/spd/p/pdf/KfEH0GobLX03aBxrcFfOrA/SE2030236.A1.pdf Patent application SE 2030236 A1]

• Zwicker tone
• Tinnitus
• Hearing aid
• Tinnitus masker
• List of people with tinnitus

Category:Companies formerly listed on Nasdaq Stockholm

Category:Medical device manufacturers

Category:Medical and health organizations based in Sweden

Category:Medical technology companies of Sweden

Category:Medical equipment

Category:Hearing aid manufacturers

Category:Companies based in Malmö

Category:Organizations based in Malmö

Category:Organizations based in Sweden

Category:Swedish brands

{{Portal bar|Companies|Sweden}}